°×С½ãÂÛ̳

Links

ucl.ac.uk/medicine/amyloidosis">°×С½ãÂÛ̳ Centre for Amyloidosis and Acute Phase Proteins

As reported in the Financial Times today, GlaxoSmithKline (GSK) has announced it aims to sign up 10 academic 'superstars' for long term partnerships to develop medicines more cost effectively.

°×С½ãÂÛ̳ Business is delighted to announce that the first academic 'superstar' to be chosen is Professor Mark Pepys (°×С½ãÂÛ̳ Division of Medicine).

Professor Pepys started up the °×С½ãÂÛ̳-spin out Pentraxin Therapeutics, which is developing a treatment for a rare form of amyloidosis.Ìý

Professor Pepys said:Ìý"It's a wonderful idea and we are delighted to be working with GSK to develop new medicines for patients."

GSK aims to work closely with leading external medical researchers until the launch of a new drug. This will allow GSK to tap their expertise while providing them with facilities, funding and incentives to be paid if a treatment proves successful.

---

Related News

About Pentraxin Therapeutics Ltd

Pentraxin Therapeutics Ltd is a company spun out of °×С½ãÂÛ̳ by °×С½ãÂÛ̳ Business (°×С½ãÂÛ̳B). Formed in 2001, it holds all the intellectual property and proprietary knowledge emanating from the research of Professor Mark Pepys at °×С½ãÂÛ̳. ÌýMajor IP within Pentraxin covers treatments for amyloidosis and amyloid-related diseases such as Alzheimer's disease and type II diabetes, as well as targeting the pathogenic effects of C‑reactive protein in cardiovascular disease and inflammatory diseases.

About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at

About °×С½ãÂÛ̳B

°×С½ãÂÛ̳ Business plc is responsible for commercialising innovations arising from the research base at °×С½ãÂÛ̳, one of the UK's leading research-led universities. °×С½ãÂÛ̳ Business undertakes a broad range of knowledge transfer activities, covering the facilitation of consultancy and collaborative research engagements through to technology transfer, company incubation and investment. More information on °×С½ãÂÛ̳ Business can be found at